Millennium Capital Advisors LLC Invests $595,000 in Stryker Corporation $SYK

Millennium Capital Advisors LLC acquired a new position in shares of Stryker Corporation (NYSE:SYK) in the 4th quarter, Holdings Channel reports. The fund acquired 1,694 shares of the medical technology company’s stock, valued at approximately $595,000.

Several other institutional investors have also modified their holdings of the stock. Noesis Capital Mangement Corp lifted its position in shares of Stryker by 3.6% during the 4th quarter. Noesis Capital Mangement Corp now owns 69,303 shares of the medical technology company’s stock worth $24,358,000 after buying an additional 2,394 shares during the last quarter. Qsemble Capital Management LP increased its holdings in shares of Stryker by 758.1% in the 4th quarter. Qsemble Capital Management LP now owns 22,679 shares of the medical technology company’s stock valued at $7,971,000 after acquiring an additional 20,036 shares during the period. Financial Security Advisor Inc. acquired a new position in shares of Stryker in the 4th quarter valued at $900,000. Novare Capital Management LLC increased its holdings in shares of Stryker by 8.8% in the 4th quarter. Novare Capital Management LLC now owns 38,571 shares of the medical technology company’s stock valued at $13,557,000 after acquiring an additional 3,134 shares during the period. Finally, AlphaCore Capital LLC increased its holdings in shares of Stryker by 146.4% in the 4th quarter. AlphaCore Capital LLC now owns 3,247 shares of the medical technology company’s stock valued at $1,141,000 after acquiring an additional 1,929 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In related news, VP M Kathryn Fink sold 5,220 shares of Stryker stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares in the company, valued at $3,728,937.45. This trade represents a 28.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 4.60% of the stock is currently owned by company insiders.

Stryker Stock Performance

NYSE:SYK opened at $306.74 on Friday. The firm’s fifty day moving average price is $329.68 and its 200 day moving average price is $351.73. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The firm has a market cap of $117.59 billion, a price-to-earnings ratio of 35.50, a price-to-earnings-growth ratio of 1.93 and a beta of 0.80.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. During the same quarter last year, the business earned $2.84 earnings per share. The business’s quarterly revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, sell-side analysts expect that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is 40.74%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on SYK. Weiss Ratings cut shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 4th. Barclays cut their target price on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $361.00 target price on shares of Stryker in a report on Friday, May 1st. Citigroup cut their target price on shares of Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Finally, UBS Group cut their target price on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a report on Tuesday, March 17th. Sixteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $395.48.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.